George A Ricca

Title: The Innovations of George A. Ricca

Introduction

George A. Ricca is a notable inventor based in Blue Bell, Pennsylvania. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies and their therapeutic applications. With a total of 2 patents, his work has had a profound impact on cancer treatment and molecular biology.

Latest Patents

Ricca's latest patents include groundbreaking inventions. One patent focuses on monoclonal antibodies specific to the human epidermal growth factor receptor. These antibodies are capable of inhibiting the growth of human tumor cells that express these receptors. The therapeutic uses of these monoclonal antibodies, both alone and in combination with anti-neoplastic agents, are also disclosed. Another patent involves expression cloning of c-src SH3-domain binding proteins. This invention provides a unique SH3 binding domain core motif and cDNA clones encoding proteins that interact with the SH3 domain of c-src. The method described may be used to identify SH3-binding proteins and select compounds that influence this binding.

Career Highlights

Throughout his career, George A. Ricca has worked with prominent companies in the pharmaceutical industry. He has been associated with Rhone-Poulenc Rorer International (Holdings), Inc. and Rhone-Poulenc Rorer Pharmaceuticals Inc. His work in these organizations has contributed to advancements in drug development and therapeutic methods.

Collaborations

Ricca has collaborated with notable professionals in his field, including Christopher Cheadle and Victoria J. South. These collaborations have likely enhanced the scope and impact of his research and inventions.

Conclusion

George A. Ricca's contributions to biotechnology and his innovative patents have paved the way for advancements in cancer treatment and molecular biology. His work continues to influence the scientific community and improve therapeutic options for patients.